


# DENGUE VACCINE DEVELOPMENT AND VALIDATION TIMELINE

Last updated: 8<sup>th</sup> May 2018



1. <http://apps.who.int/iris/handle/10665/67783> - Guidelines for the evaluation of dengue vaccines in populations exposed to natural infection - UNDP/World Bank/WHO Initiative for Research and Training in Tropical Diseases; WHO Initiative for Vaccine Development (WHO/TDR/IVR/DEN/02.1, 2002)
2. [http://whqlibdoc.who.int/hq/2008/WHO\\_IVB\\_08.12\\_eng.pdf?ua=1](http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.12_eng.pdf?ua=1)
3. Sabchareon, Arunee, et al., "Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial." *The Lancet*, September 2012. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(12\)61428-7/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61428-7/abstract)
4. WHO guidelines [http://www.who.int/immunization/research/committees/dengue\\_tag/en/](http://www.who.int/immunization/research/committees/dengue_tag/en/) last accessed March 2018
5. Capeding MR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet* 2014;384:1358-65.
6. Villar L, et al. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America N Engl J Med 2015;372:113-23.
7. [http://www.who.int/immunization/policy/sage/sage\\_wg\\_dengue\\_mar2015/en/](http://www.who.int/immunization/policy/sage/sage_wg_dengue_mar2015/en/) last accessed March 2018
8. Ferguson et al. *Science* 2016 Sep. doi: 10.1126/science.1249590 Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment - Neil M. Ferguson, Isabel Rodriguez-Barraquer, Iaria Dorigatti, Luis Mlery-Teran-Romero, Daniel J. Laydon and Derek A.T. Cummings (September 1, 2016)
9. Flasche et al. *PLoS Med* 2016 Nov. doi: 10.1371/journal.pmed.1002181. eCollection 2016 Nov. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Tetravalent Dengue Vaccine (Dengvaxia): A Model Comparison Study.
10. Vannice, Kirsten, et al. The value of multi-country joint regulatory reviews: The experience of a WHO joint technical consultation on the CYD-TDV (Dengvaxia®) dossier. *Vaccine*. 13 October 2017
11. Hadinegoro, S.R. et al. Efficacy and Long-Term Safety of a dengue vaccine in regions of endemic disease. *N Engl J Med* 2015;373:1195-206. DOI: 10.1056/NEJMoa1506223
12. Guy, Bruno & Nick Jackson. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. *Nature reviews Microbiology*. 7 dec 2015 4, pages45-54 (2016) doi:10.1038/nmicro.2015
13. [http://www.who.int/immunization/policy/sage/sage\\_wg\\_dengue\\_mar2015/en/](http://www.who.int/immunization/policy/sage/sage_wg_dengue_mar2015/en/) last accessed March 2018
14. Gailhardou et al. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. *PLoS Negl Trop Dis*. 2016 Jul 14;10(7):e0004821. doi: 10.1371/journal.pntd.0004821
15. Cortez et al. Long-Term Safety of a CYD-TDV Vaccine in Latin American Dengue Endemic Countries. – Poster LB-5290 ASTMH, Nov 2016
16. Limkittikul, Kriengsak, et al. Long-term (6-year) follow-up in Thai children from phase IIb proof of concept efficacy study of cyd-tdv dengue vaccine. Presentation at ACPID, Bangkok, Thailand, 7 – 10 November 2016.
17. Maria Rosario Capeding, Carina Frago et al Long-Term Safety (Year 5) of the Recombinant Live-Attenuated Chimeric-Yellow Fever-Dengue Virus Tetravalent Dengue Vaccine (CYD-TDV) in Asian Phase III Efficacy Trial. Presentation at the 20<sup>th</sup> Annual Conference on Vaccine Research 24 April 2017
18. Arredondo-García JL, et al., Four-year safety follow-up of the tetravalent dengue vaccine (dengvaxia): efficacy randomized controlled trials in Asia and Latin America. *Clinical Microbiology and Infection* (2018), <https://doi.org/10.1016/j.cmi.2018.01.018>
19. [https://www.sanofipasteur.com/media/Project/One-Sanofi-Web/sanofipasteur-com/en/home/PR\\_201711130\\_SanofiUpdatesInfoOnDengueVaccine\\_EN.pdf](https://www.sanofipasteur.com/media/Project/One-Sanofi-Web/sanofipasteur-com/en/home/PR_201711130_SanofiUpdatesInfoOnDengueVaccine_EN.pdf)
20. <http://www.who.int/immunization/QA-dengue-vaccine.pdf>
21. Vannice, Kirsten, et al. Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. *Vaccine*. *Vaccine*. 2018 Mar 7. pii: S0264-410X(18)30249-4. doi: 10.1016/j.vaccine.2018.02.062 <https://www.sciencedirect.com/science/article/pii/S0264410X18302494?via=ihub>
22. [https://www.sanofipasteur.com/media/Project/One-Sanofi-Web/sanofipasteur-com/en/media-room/docs/Company\\_Statement\\_on\\_SAGE\\_19042018\\_FINAL\\_EN-v2.pdf](https://www.sanofipasteur.com/media/Project/One-Sanofi-Web/sanofipasteur-com/en/media-room/docs/Company_Statement_on_SAGE_19042018_FINAL_EN-v2.pdf)